Compare PUMP & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUMP | PRCT |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2017 | 2021 |
| Metric | PUMP | PRCT |
|---|---|---|
| Price | $9.52 | $17.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $14.14 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,158,000.00 | $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | $15.61 | $24.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $4.87 | $16.67 |
| 52 Week High | $18.50 | $38.11 |
| Indicator | PUMP | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 38.53 |
| Support Level | $8.96 | $16.89 |
| Resistance Level | $10.55 | $29.27 |
| Average True Range (ATR) | 0.51 | 0.96 |
| MACD | -0.11 | -0.29 |
| Stochastic Oscillator | 0.75 | 7.26 |
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.